<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04904276</url>
  </required_header>
  <id_info>
    <org_study_id>O-FOSTA-901</org_study_id>
    <nct_id>NCT04904276</nct_id>
  </id_info>
  <brief_title>Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy</brief_title>
  <official_title>Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy (FORTE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigel Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigel Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate patient characteristics, treatment patterns, clinical outcomes and safety of&#xD;
      fostamatinib as second-line therapy in real-world clinical practice, for the treatment of ITP&#xD;
      in adult patients who have an insufficient response to prior therapy (steroids ±&#xD;
      immunoglobulins).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate patient characteristics, treatment patterns, clinical outcomes and safety of&#xD;
      fostamatinib as second-line therapy in real-world clinical practice, for the treatment of ITP&#xD;
      in adult patients who have an insufficient response to prior therapy (steroids ±&#xD;
      immunoglobulins).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fostamatinib dosing</measure>
    <time_frame>12-month observation period</time_frame>
    <description>Changes is fostamatinib dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet counts over time during the course of fostamatinib therapy</measure>
    <time_frame>12-month observation period</time_frame>
    <description>Platelet count and change from baseline in platelet count over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Use of concomitant medications related to ITP</measure>
    <time_frame>12-month observation period</time_frame>
    <description>Use of concomitant medications related to ITP during the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Use of ITP Rescue Medication</measure>
    <time_frame>12-month observation period</time_frame>
    <description>The number of patients with ITP rescue medication use at any time during the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of fostamatinib</measure>
    <time_frame>12-month observation period</time_frame>
    <description>Evaluate continued safety of fostamatinib in ITP patients through adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ITP-PAQ Quality of life measure</measure>
    <time_frame>12-month observation period</time_frame>
    <description>Use of the score from questionnaire to assess disease-specific quality of life in adults with ITP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment satisfaction measure (MSQ)</measure>
    <time_frame>12-month observation period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SF-36 Quality of life measure</measure>
    <time_frame>12-month observation period</time_frame>
    <description>Scale of functional health and well-being from the patient's point of view.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>ITP</condition>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Initiating treatment with fostamatinib as second-line therapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Treated with fostamatinib for at least 12 weeks as second-line therapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Fostamatinib disodium</description>
    <arm_group_label>Initiating treatment with fostamatinib as second-line therapy</arm_group_label>
    <arm_group_label>Treated with fostamatinib for at least 12 weeks as second-line therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This two-cohort study will enroll approximately 45 patients diagnosed with ITP. Cohort 1&#xD;
        will enroll approximately 30 ITP patients who will begin treatment with fostamatinib as&#xD;
        second-line therapy. Cohort 2 will enroll approximately 15 patients who have a record of at&#xD;
        least 12 weeks of fostamatinib treatment as second-line therapy, with the intent to&#xD;
        continue, at time of enrollment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide written informed consent&#xD;
&#xD;
          2. Diagnosis of ITP in adult patients (≥ 18 years of age) with an insufficient response&#xD;
             to steroids ± immunoglobulins and requiring a change in therapy&#xD;
&#xD;
          3. For Cohort 1, intent to initiate fostamatinib at enrollment as change in therapy&#xD;
&#xD;
          4. For Cohort 2, currently undergoing treatment with fostamatinib as second line therapy&#xD;
             for at least 12 weeks, with the intent to continue, at the time of enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any prior ITP therapy/treatment other than steroids ± immunoglobulins (e.g. rituximab,&#xD;
             thrombopoietin receptor agonists (TPO), splenectomy)&#xD;
&#xD;
          2. Participation in any interventional study during the course of this study&#xD;
&#xD;
          3. Lack of historical platelet counts, at time of fostamatinib initiation for those&#xD;
             entering Cohort 2&#xD;
&#xD;
          4. Pregnant and/or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robert Numerof, Ph.D.</last_name>
    <phone>650-624-1100</phone>
    <email>rnumerof@rigel.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Simmons Cancer Institute at Southern Illinois University</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruchika Goel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ruchika Goel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A</name>
      <address>
        <city>Clinton</city>
        <state>Maryland</state>
        <zip>20735</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Mendoza, MD</last_name>
      <phone>877-664-7724</phone>
    </contact>
    <investigator>
      <last_name>Mohit Narang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohit Narang, MD</last_name>
      <phone>877-664-7724</phone>
    </contact>
    <investigator>
      <last_name>Mohit Narang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Wallmark, MD</last_name>
      <phone>877-664-7724</phone>
    </contact>
    <investigator>
      <last_name>Mohit Narang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kashif Ali, MD</last_name>
      <phone>877-664-7724</phone>
    </contact>
    <investigator>
      <last_name>Mohit Narang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hughes, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Hughes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Afzal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amber Afzal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates, LLC</name>
      <address>
        <city>Little Silver</city>
        <state>New Jersey</state>
        <zip>07739</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Horkheimer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ian Horkheimer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune Thrombocytopenia</keyword>
  <keyword>ITP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

